

Acquisition Search: Drug Discovery CROs

About the Acquirer

- Dutch PE-owned;
- Drug discovery CROs;
- Tailor-made synthetic solutions for the design and synthesis of small molecules;
- Clients include large European pharma and biotech companies;
- Headquartered in the Netherlands with services offered across Europe.

Acquisition Criteria

- Drug discovery CROs;
- Located in Benelux and CEE;
- Minimum EBITDA €2m.

Enquiries should be directed to Helen Postlethwaite at Langcliffe International via email helen.postlethwaite@langcliffeinternational.com.